Diabetes News and Research

Latest Diabetes News and Research

Men with type 1 diabetes could grow their own insulin-producing cells from testicular tissue, says GUMC

Men with type 1 diabetes may be able to grow their own insulin-producing cells from their testicular tissue, say Georgetown University Medical Center (GUMC) researchers who presented their findings today at the American Society of Cell Biology 50th annual meeting in Philadelphia.

13 Dec 2010

Gift cards from fast food joints cause outrage among health experts

As Australia battles with the obesity epidemic, fast food outlet KFC has raised eyebrows from health quarters by offering Christmas gift cards worth up to $500. A survey of fast-food outlets in Hobart’s CBD yesterday revealed gift vouchers were available at McDonald’s, KFC and Subway.

12 Dec 2010

Access announces $6.0 million registered direct offering

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of $2.55 per share for aggregate gross proceeds of $6.0 million.

10 Dec 2010

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested

10 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

First genetic test on developing risk of Alzheimer's disease and heart attacks

Alzheimer and heart attacks have been found to share common genetic basis. The research leads the way to the first genetic test on developing the risk of the diseases even at a young age. According to Federico Licastro, an immunologist at the University of Bologna who coordinated the study published in the scientific journal, Journal of Alzheimer's Disease, a test is now ready. "They are already selling it in America", he says, citing the case of a private firm in New Mexico (USA) that collaborated on the study. "But the tests could easily be also conducted wherever, using a simple blood test".

10 Dec 2010

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients - those with estrogen receptor (ER)-positive/HER2-negative disease.

10 Dec 2010

Exercise can help prevent or manage diabetes, boost quality of life: New guidelines

New guidelines on exercise for people with diabetes are likely to open some eyes — and, for those who follow them, help prevent or manage diabetes, improve overall health and boost quality of life. A panel of nine experts developed the recommendations, published this month in Medicine & Science in Sports & Exercise, the official journal of the American College of Sports Medicine.

10 Dec 2010

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.

9 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.

9 Dec 2010

Dogs help understand primary ciliary dyskinesia

A dog is mankind's best friend : the old saying has once again been borne out through a medical discovery concerning the genetic origins of primary ciliary dyskinesia (PCD). In using dogs as a research model in the framework of the European LUPA project, a team from the University of Liège's GIGA-Research Unit has been able to bring to light new mutations in a specific gene responsible for the development of the disease in human beings.

9 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

New report indicates that struggling economy may have reduced use of preventive care

A new report released by non-profit health care organization MN Community Measurement, indicates that the struggling economy may have reduced the use of preventive care, including breast cancer screenings and childhood immunizations, as well as the on-going care needed for chronic diseases like diabetes and vascular disease.

9 Dec 2010

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Patients treated by Welsh hospitals for upper gastrointestinal (GI) bleeding were 41% more likely to die if they were admitted on a public holiday and 13% more likely if it was at the weekend, according to research in the January issue of Alimentary Pharmacology and Therapeutics.

9 Dec 2010

Insulin related calls to poison centers increase 279%

Annual calls to poison centers regarding insulin have skyrocketed by 279 percent over the past 10 years, according to a new study authored by medical professionals at four U.S. poison centers.

9 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Laparoscopic approach still best for most patients, not for all: Study

If skin is the body's fortress against germ invaders, shouldn't minimally invasive surgeries - operations guided by camera probes, conducted entirely within the abdomen - carry less risk for serious infection than procedures that slice the same cavity wide open?

9 Dec 2010

Researchers to study effect of resveratrol on impaired IGT in older prediabetic patients

Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded $600,000 from the American Diabetes Association to study the effect of resveratrol, a chemical compound most notably found in red wine and grapes, on impaired glucose tolerance in older adults.

9 Dec 2010

Diabetes News and Research

Latest Diabetes News and Research

Men with type 1 diabetes could grow their own insulin-producing cells from testicular tissue, says GUMC

Gift cards from fast food joints cause outrage among health experts

Access announces $6.0 million registered direct offering

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

First genetic test on developing risk of Alzheimer's disease and heart attacks

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Exercise can help prevent or manage diabetes, boost quality of life: New guidelines

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Expert discusses androgen deprivation therapy for prostate cancer

Acorda initiates enrollment in GGF2 Phase 1 clinical trial in patients with heart failure

Dogs help understand primary ciliary dyskinesia

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

New report indicates that struggling economy may have reduced use of preventive care

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Insulin related calls to poison centers increase 279%

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Laparoscopic approach still best for most patients, not for all: Study

Researchers to study effect of resveratrol on impaired IGT in older prediabetic patients

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in